Acrivon Therapeutics, Inc.
ACRV
$1.52
-$0.06-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.09% | -3.78% | 0.86% | 0.86% | 13.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.39% | -21.69% | 5.65% | 22.61% | 18.53% |
| Operating Income | 19.39% | 21.69% | -5.65% | -22.61% | -18.53% |
| Income Before Tax | 16.85% | 18.75% | -11.75% | -19.37% | -18.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.85% | 18.75% | -11.75% | -19.37% | -18.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.85% | 18.75% | -11.75% | -19.37% | -18.59% |
| EBIT | 19.39% | 21.69% | -5.65% | -22.61% | -18.53% |
| EBITDA | 19.86% | 22.30% | -5.21% | -22.40% | -17.92% |
| EPS Basic | 17.74% | 19.70% | -4.98% | 29.68% | 30.73% |
| Normalized Basic EPS | 27.80% | 19.72% | -4.95% | 29.69% | 22.02% |
| EPS Diluted | 17.74% | 19.70% | -4.98% | 29.68% | 30.73% |
| Normalized Diluted EPS | 27.80% | 19.72% | -4.95% | 29.69% | 22.02% |
| Average Basic Shares Outstanding | 1.09% | 1.20% | 6.45% | 69.76% | 71.22% |
| Average Diluted Shares Outstanding | 1.09% | 1.20% | 6.45% | 69.76% | 71.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |